Results 161 to 170 of about 6,539 (200)

Benralizumab for asthma.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Benralizumab

Reactions Weekly
  +11 more sources

Benralizumab

Reactions Weekly, 2022
  +7 more sources

Benralizumab

Reactions Weekly, 2023
openaire   +2 more sources

Benralizumab: First Global Approval

Drugs, 2018
Kyowa Hakko Kirin, AstraZeneca and subsidiaries are developing benralizumab (Fasenra™)-a humanised anti-interleukin-5 receptor alpha chain (IL-5Rα) monoclonal antibody-as a treatment of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD).
openaire   +2 more sources

Benralizumab

Reactions Weekly, 2021
openaire   +2 more sources

Benralizumab

Drugs of the Future, 2014
openaire   +1 more source

Benralizumab for Chronic Spontaneous Urticaria

New England Journal of Medicine, 2020
Umesh Singh, Jonathan A Bernstein, Xiang Zhang   +2 more
exaly  

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Lancet Respiratory Medicine,the, 2022
Andrew Menzies-Gow, Mark Gurnell, Liam G Heaney   +2 more
exaly  

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2016
J Mark Fitzgerald, Eugene R Bleecker, Parameswaran Nair   +2 more
exaly